Short answer · Medically reviewed summary · Last updated: 2026-05-08
Glioma does not have a single, universal ICD code because it encompasses a broad group of tumors originating from glial cells; however, the primary classification falls under ICD-10 code C71 (Malignant neoplasm of brain) and ICD-9 code 191. Because Glioma severity varies significantly by grade and location, clinicians use these codes to categorize the malignancy and site within the central nervous system. How are ICD codes used to classify Glioma? The coding system for Glioma relies on the anatomical site of the tumor within the brain, as well as the histological grade as defined by the World Health Organization (WHO).
ICD10 code of Glioma and ICD9 code
ICD-10 and ICD-9 codes for Glioma, with classification details for clinicians, coders and patients.
Glioma does not have a single, universal ICD code because it encompasses a broad group of tumors originating from glial cells; however, the primary classification falls under ICD-10 code C71 (Malignant neoplasm of brain) and ICD-9 code 191. Because Glioma severity varies significantly by grade and location, clinicians use these codes to categorize the malignancy and site within the central nervous system.
How are ICD codes used to classify Glioma?
The coding system for Glioma relies on the anatomical site of the tumor within the brain, as well as the histological grade as defined by the World Health Organization (WHO). While ICD-10 C71 is the standard for malignant Glioma, specific sub-codes (C71.0–C71.9) are used to designate the exact location, such as the frontal lobe or brain stem. These codes are essential for medical billing, tracking incidence rates, and coordinating care for the 34 members of the DiseaseMaps.org community living with this diagnosis.
What diagnostic criteria define a Glioma?
Diagnosis of Glioma is typically confirmed through a combination of neuroimaging and histopathological analysis. The clinical management of Glioma is currently guided by the WHO classification system, which integrates both the tumor’s appearance under a microscope and its molecular characteristics. Common markers used in classification include:
- IDH mutation status: Critical for differentiating between specific types of astrocytoma and oligodendroglioma.
- 1p/19q codeletion: A key diagnostic feature for defining oligodendrogliomas.
- MGMT promoter methylation: Often tested to predict the responsiveness of Glioma to alkylating chemotherapy agents.
- WHO Grade (1-4): Indicates the rate of growth and potential aggressiveness of the Glioma cells.
Next steps
- Consult with a neuro-oncologist to ensure your specific tumor subtype is accurately classified for treatment planning.
- Request a copy of your pathology report to understand the molecular markers identified in your Glioma.
- Connect with the 34 other members on DiseaseMaps.org to share experiences and supportive resources.
- Discuss clinical trials targeting specific genetic mutations with your primary care team.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult with a qualified healthcare professional regarding your specific diagnosis and treatment plan.
References
- World Health Organization (WHO) Classification of Tumours of the Central Nervous System.
- NIH National Cancer Institute (NCI) - Adult Brain Tumors Treatment (PDQ).
- Orphanet (ORPHA:35716) - Rare glioma classifications.
- ICD-10 Version: 2019 (International Classification of Diseases).
